Loading...
Loading...
By Sofía Garduño - Thu, 12/05/2024 - 12:06
COFEPRIS approves LEQEMBI for early Alzheimer’s disease, which reduces disease progression and cognitive decline.
Featured content
Partnership Content
https://mexicobusiness.news/tag/eisai
More Health
By MBN Staff - Wed, 07/31/2024 - 17:22
Leqembi's data shows a 31% reduction in cognitive decline, with no new safety issues, contrasting with Lilly’s Kisunla in cost and approach.
